MitoRx Therapeutics Ltd, a developer of mitochondrial-targeted therapeutics, has appointed Xavier Jacq as chief scientific officer as the company prepares for a clinical candidate nomination in its lead indication of the treatment of obesity. Dr Jacq has extensive experience in small molecule drug development and mitochondrial biology. He was most recently CSO at Moa Technologies in Oxford, UK, and previously held scientific leadership roles at Almac Group and Mission Therapeutics, and led projects at KuDOS and Sanofi. He has a PhD in biochemistry from Université Louis Pasteur (Strasbourg I), France and a post doc in oncology from Columbia University, US.
MitoRx Therapeutics announced the appointment on 1 May 2025.
Copyright 2025 Evernow Publishing Ltd.